Revolutionary Antibody Technology: Human Immunoglobulin G (hIgG) to Treat and Prevent Autoimmune Disorders
With our unique technology platform, SAB BIO is the only company that can produce targeted, fully human, multi-specific polyclonal antibodies without the need for human donors through our Tc Bovine platform.
At SAB BIO, we are always looking for partners who share our goal of addressing pressing health challenges. Interested in partnership opportunities? Contact us here.
SAB-142: Potential Disease-modifying Immunotherapy Being Developed to Delay the Onset and Progression of Type 1 Diabetes
Current treatment approaches for type 1 diabetes (T1D) focus primarily on daily disease management with insulin monitoring and administration to prevent complications, but these do not change the trajectory of the disease.
- Early intervention is essential and life-long disease modification is possible with effective, safe, and reliable redosing.
- Our goal is to develop a T1D therapy that immunomodulates T cells to preserve C-peptide while avoiding immunosuppression.
- SAB-142 is a potentially disease-modifying, redosable immunotherapy being developed to delay the onset and progression of Stage 3 Type 1 Diabetes.
- SAB-142 works by directly targeting multiple immune cells involved in destroying pancreatic beta cells, including the modulation of “bad acting” T-lymphocytes.
- SAB-142’s mechanism of action, like rabbit ATG (rATG), directly modulates multiple immune cells involved in destroying pancreatic beta cells.
- However, SAB-142 provides a better safety profileresulting in no serum sickness and low/no immunogenicity – this offers the potential for life-long disease modification through redosing safely, preserving C-peptide and delaying the onset or progression of T1D.
- By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.
- C-peptide is a stable marker of endogenous insulin production.
- Preserving beta cell function and thus insulin production as measured by C-peptide is key to delaying progression of T1D.
SAB-142 has the Potential for Broadest Use with Superior Safety, Efficacy, and Patient Convenience in a Broad Age Range of T1D Patients
T1D: Progressive Autoimmune Disease with Significant
Long-term Burden
